Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Amlitelimab study met its goals but results were not meaningfully better than Dupixent ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.